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Application of viral vector in gene therapy and vaccination is still limited by their structural stability, which signiﬁcantly increased avoidable cost in
storage and transportation. Herein a non-covalent conjugated low-pH degradable nanocapsule has been adopted to stabilize viral vectors. By utilizing a
luciferase expressing adenovirus, AdCMVLuc, we succeeded in a raise of over 11 folds in AdCMVLuc's structural stability after 12 days storage at 4 1C.
& 2014 Chinese Materials Research Society. Production and hosting by Elsevier B.V. All rights reserved.
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Adenovirus is one of the most commonly used DNA viral
vectors and widely accepted to be a safe and effective gene
carrier in vaccination and gene therapy trials [1–7]. However,
most of the currently available live viral vaccines are lyophi-
lized products, and none of them provides sufﬁcient structural
stability to obviate the manufacturers' requirements for storage
at 4–8 1C or even below 20 1C. At current state of the art,
cold storage is major preference for viral vectors, however
even in the developed world, the cold chain accounts for up to
14% of the vaccination costs [8,9]. More importantly, recent
studies showed that adenovirus with alternated genome,
usually smaller than wide-type's, presented dramatically lower
structural stability than original adenovirus [10,11]. Therefore10.1016/j.pnsc.2014.03.001
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based vaccine or gene therapy vectors would signiﬁcantly
reduce the cost of delivery as well as increase the overall
efﬁcacy especially for the developing world [12].
Here, we present a facile approach to synthesize highly
stabilized adenovirus nanocapsule through non-covalent interaction
and in situ polymerization. The non-covalent electric interaction
between positively charged monomers and negatively charged
virion is utilized as anchors of polymer shell and acid degradable
crosslinkers are added into co-polymerization. Therefore protective
polymer shell will dissemble at low-pH in lysosome and adeno-
virus could be released. The proposed nanocapsule is a general
solution to various viral vectors, as no speciﬁc binding site or
modiﬁcation on viral vector is required.
As illustrated in Fig. 1, lab-made positively charged monomers,
NTris (please refer to materials and method), and low-pH
degradable crosslinkers, glycerol dimethacrylate (GDMA), are
in situ polymerized around adenovirus in an aqueous solution.
The opposite charges on NTris and virion facilitate individual
wrapping of each adenovirus. Such a crosslinked shell can protect
the encapsulated adenovirus from structural denaturation and is
readily degradable in acidic environment, such as pH 5.4. We
believe that this unique, inducible design will provide adenovirus
with outstanding stability during economical 4 1C storage andElsevier B.V. All rights reserved.
Fig. 1. In situ encapsulation of individual adenovirus and in vivo low-pH
triggered viral release.
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upon entering the acidic endosomal/lysosomal compartments. A
luciferase expressing adenoviral vector, AdCMVLuc, is employed
to demonstrate gene transfer efﬁciency of as-proposed nanocapsule
via luciferase assay.
2. Materials and methods
2.1. Materials
All chemicals were purchased from Sigma-Aldrich unless
otherwise noted, and were used as received. Luciferase assay
kit was purchased from Promega, cat# E1501.
2.2. Synthesis of positively charged monomers
In a typical synthesis, 0.492 mmol of methacrylic anhydride and
0.615 mmol of triethylamine were dissolved in 1 mL of acetonitrile
in the ice/water bath with vigorous stirring, marked as solution A.
Then 20 mg tris(2-aminoethyl)amine was dissolved in another
1 mL of acetonitrile, dripped into solution A and reacted for 8 h.
The solution was dried under vacuum and dark condition. After
that, the compound was dissolved in 500 mL methanol and isolated
by the silica gel chromatography, which mobile phase was chloro-
form and methanol with volume ratio 12:1. Final product was
named as NTris for convenience. Puriﬁed NTris was dried under
vacuum and dark condition then stored under 80 1C.
2.3. Synthesis of adenovirus nanocapsules
AdCMVLuc has been employed as the model delivery vector,
also been referred as NativeAdv and the native adenovirus in later
description. Typically, 10 mL of AdCMVLuc solution (0.5 mg/mL
in 10 mM tris buffer with 1 mM Mg2þ , pH 8), 1 mL of NTrisDMSO solution (4%), 1 mL of glycerol dimethacrylate (GDMA)
DMSO solution (4%), 6.4 mL of ammonium persulphate in
aqueous solution (dilute 100 times from fresh prepared 5 wt%
aqueous solution), 6.4 mL of N,N,N0,N0-tetramethylethylenedia-
mine aqueous solution (dilute 100 times from fresh prepared 1%
aqueous solution) and 75.2 mL of tris buffer (10 mM tris buffer
with 1 mM Mg2þ , pH 8) were mixed and reacted in ice bath for
2 h. Then adenovirus nanocapsules were dialyzed to the same tris
buffer with Mg2þ .
2.4. Transmission electron microscope (TEM) imaging
TEM images of nanocapsules were obtained with a Philips
EM120 Transmission Electron Microscope. Before the obser-
vation, nanocapsules were negatively stained using 1% pH 7.0
phosphotungstic acid (PTA) solution.
2.5. Zeta potential
Zeta potential and particle size distribution were measured with
a Malvern particle sizer Nano-ZS. Size of adenovirus nanocapsule
was characterized in 10 mM pH 8 tris buffer with 1 mM Mg2þ
and Zeta of adenovirus nanocapsule was collected in 2.5 mM pH 8
tris buffer with 0.25 mM Mg2þ .
2.6. Infectivity and structural stability of adenovirus
nanocapsule in HeLa cells Day 1, adenovirus nanogels were synthesized and dialyzed
with 10 mM tris buffer with 1 mM Mg2þ , pH 8 for overnight.
48 well plates were seeded with HeLa cells (1 104 cell
per well). Day 2, dialyzed adenovirus nanogel and native adenovirus
were aliquot to 20 mL per 1.5 mL centrifuge tubes and
stored at 4 1C. Firstly certain amount of native adenovirus
and adenovirus nanocapsules were added into 48 well plate
seeded on Day 1 to achieve MOI¼10, immediately after
diluted to 5 times in volume with 1 M pH 5 acetate buffer.
All the samples were tested in triplicates. Finally infected
cell plate was incubated for 3 days and luciferase assays
were carried out to determine infectivity. Day 5, luciferase assays were carried out to determine the
infectivity of freshly prepared adenovirus nanogel. Day 11, 48 well plates were seeded with HeLa cells
(1 104 cell per well). Day 12, the same process of Day 2 was repeated.
 Day 15, luciferase assays were carried out for the infection
on Day 12, to determine the stability of as-prepared
adenovirus nanogel.
2.7. Luciferase assay
The standard protocol for Fireﬂy Luciferase Assay kit (Promega,
cat# E1501) was followed [13]. Brieﬂy, infected cells were lysed
and collected into 1.5 mL centrifuge tubes and centrifuged for
Fig. 3. DLS characterization of adenovirus nanocapsules.
Fig. 4. Low-pH degradation of adenovirus nanocapsules. Adv: native adenovirus.
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chemiluminescent signals were recorded by a FB12 Single Tube
Luminometer from Berthold Detection System.
3. Results and discussion
3.1. Characterization of adenovirus nanocapsule
Electron microscopy was used to visualize adenovirus nano-
capsules. Native adenoviruses and nanocapsules were deposited
onto carbon-coated copper grids separately; phosphotungstic acid
staining was applied to increase the contrast. Fig. 2a shows the
icosahedral structure of native adenoviral virion with a diameter
around 80 nm. Fig. 2b indicates that adenovirus nanocapsules have
a round polymer shell with thickness of 10 nm. The inset Fig. 2c
with higher magniﬁcation for an individual adenovirus nanocap-
sule also suggests that the adenovirus inside the polymer shell has
maintained structural integrity.
Dynamic light scattering (Fig. 3) shows the diameter of
adenovirus nanocapsule increased to around 95 nm from 80 nm
as of native adenovirus, which is coincident with direct observation
from TEM images. Meanwhile zeta potential of adenovirus nano-
capsules is around 27 mV in pH 8 tris buffer with Mg2þ , which
suggests that as-prepared nanocapsules are thermodynamically
stable.
3.2. Low-pH degradation of adenovirus nanocapsule
As-prepared adenovirus nanocapsules in phosphate buffered
saline were mixed with pH 5 acetic buffer to achieve pH 5.4 and
mimic the acidic environment in lysosomes. Then size changes of
nanocapsules were recorded by DLS characterization and plotted
in Fig. 4. Consistent with our hypothesis, polymer shell of as-
prepared adenovirus nanocapsules decreases rapidly from 100 nm
at 0 min to native adenovirus size at 30 min, which suggests the
removal of the polymer shell and the exposure of the virion.
Moreover, no size signal can be detected after 40 min in intenseFig. 2. Transmission electron microscopy (TEM) images of native adenoviruses a
adenovirus with diameters about 80 nm. (b) and (c) Adenoviruses are encapsulate
maintained inside the polymer shell.low-pH environment, implying that adenovirus has lost structural
integrity in only 10 min without the protection from polymer
shells.nd adenovirus nanocapsules. (a) Icosahedral structure is observed from native
d by a 10 nm thick polymer shell and the structure integrity of adenovirus is
Fig. 5. Structural stability of native adenovirus (NativeAdv) and adenovirus nanocapsule (NTrisAdv) at 4 1C after 12 days. (a) Relative infectivity. Infectivity at
indicated time points was normalized to NativeAdv. (b) Speciﬁc infectivity.
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Structural stability of native adenovirus (NativeAdv) and
adenovirus nanocapsules (NTrisAdv) were compared at 4 1C after
12 days storage in pH 8 tris buffer with Mg2þ . As shown in
Fig. 5, nanocapsules have evidently preserved the infectivity of
adenovirus after long-term storage. Speciﬁcally, after 2 days sto-
rage, the infectivity of NTrisAdv is around 38% comparing with
that of NativeAdv (1.4 105 RLU/μL versus 3.7 105 RLU/μL).
We believe this is due to the polymer shell partially blocked
interaction between adenoviral capsid proteins and cell surface
receptors, which plays an essential role for adenovirus cell entrance
[14,15], and free radical polymerization next to the surface of
virion could partially affect some of viral surface proteins too.
While after storing at 4 1C for 12 days, dramatic enhancement in
structural stability is observed in NTrisAdv. Comparing with
NativeAdv, the infectivity of NTrisAdv has increased to 436%
(9.6 103 RLU/μL versus 2.2 103 RLU/μL). We speculate that
the polymer shell could prevent the disassembly of adenovirus
icosahedral structure and the deactivation of surface proteins from
external environment. Moreover, the negative charge (27 mV)
on adenovirus nanocapsule surface also prevents thermal dynamic
aggregation. In summary, over 11 folds of enhanced structural
stability is achieved in adenovirus nanocapsules (NTrisAdv).
4. Conclusion
We have demonstrated a one-step approach to synthesize
highly stabilized adenovirus nanocapsule through non-covalent
conjugation of low-pH degradable polymer shell. The in situ
polymerization has provided a reversible sealing of adenovirus.
The encapsulated adenovirus can be released when the protectivepolymer shell decomposes in low-pH environment. The method
presented in this study is believed as a general solution to other
negative charged gene delivery vectors and able to promote the
application of viral vectors for gene therapy and vaccination with
enhanced structural stability and reduced storage and transporta-
tion costs.
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